Suppr超能文献

强力霉素可延缓马凡综合征小鼠模型中的动脉瘤破裂。

Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome.

作者信息

Xiong Wanfen, Knispel Rebecca A, Dietz Harry C, Ramirez Francesco, Baxter B Timothy

机构信息

Department of Surgery, University of Nebraska Medical Center, Omaha, NE 68198, USA.

出版信息

J Vasc Surg. 2008 Jan;47(1):166-72; discussion 172. doi: 10.1016/j.jvs.2007.09.016.

Abstract

OBJECTIVES

Thoracic aneurysms are the main cardiovascular complication of Marfan syndrome (MFS) resulting in premature death. MFS has been associated with mutations of the gene encoding fibrillin-1 (FBN1), a major constituent of the elastic fibers. Matrix metalloproteinases (MMPs) are important in the pathogenesis of abdominal aortic aneurysms but their precise role in MFS is not clear. Doxycycline is a nonspecific MMP inhibitor. The objective of the study was to determine whether docycycline can attenuate matrix degradation and prolong the survival of mice with MFS.

METHODS

The study employed a well-characterized animal model of MFS, namely fibrillin-1 under-expressing mice (mgR/mgR mice) that die spontaneously from rupture of the thoracic aorta between 2 to 4 months of age. Mutant and wild type mice were given doxycycline in their drinking water at a concentration designed to provide 100 mg/kg/day beginning at postnatal day (PD) 1, whereas control mice were given water. Treated mice were divided into two groups. One group of animals was followed until death or for 7 months to determine lifespan. In the second group of mice, the ascending thoracic aortas were collected for histological analysis (H&E staining, trichrome staining) and zymography for examining MMP-2 and MMP-9 levels at 6 weeks.

RESULTS

MMP-2 and MMP-9 levels were higher in the thoracic aorta of mgR/mgR mice compared with wild type littermates. Doxycycline-treated mgR/mgR mice lived 132 +/- 14.6 days (n = 16) or significantly longer than untreated mutant mice (79 +/- 6.7 days, n = 30) (P < 0.01). Connective tissue staining showed that doxycycline treatment decreased elastic fiber degradation in mgR/mgR mice. Furthermore, mgR/mgR mice treated with doxycycline had lower MMP-2 and MMP-9 levels compared with untreated mgR/mgR mice.

CONCLUSIONS

This study demonstrates that doxycycline significantly delays aneurysm rupture in MFS-like mice by inhibiting expression of tissue MMP-2 and MMP-9 and thus, degradation of the elastic matrix. The results suggest that MMPs contribute to the progression of thoracic aneurysm in MFS and that doxycycline has the potential to significantly alter the course of the disease.

摘要

目的

胸主动脉瘤是马方综合征(MFS)主要的心血管并发症,可导致过早死亡。MFS与编码原纤维蛋白-1(FBN1)的基因突变有关,FBN1是弹性纤维的主要成分。基质金属蛋白酶(MMPs)在腹主动脉瘤的发病机制中起重要作用,但其在MFS中的具体作用尚不清楚。强力霉素是一种非特异性MMP抑制剂。本研究的目的是确定强力霉素是否能减轻基质降解并延长MFS小鼠的生存期。

方法

本研究采用了一种特征明确的MFS动物模型,即原纤维蛋白-1低表达小鼠(mgR/mgR小鼠),这些小鼠在2至4月龄时会因胸主动脉破裂而自发死亡。从出生后第1天(PD1)开始,给突变型和野生型小鼠饮用含强力霉素的水,其浓度设计为提供100mg/kg/天,而对照小鼠饮用普通水。将接受治疗的小鼠分为两组。一组动物跟踪观察直至死亡或观察7个月以确定寿命。在第二组小鼠中,在6周时收集升胸主动脉进行组织学分析(苏木精-伊红染色、三色染色)和酶谱分析以检测MMP-2和MMP-9水平。

结果

与野生型同窝小鼠相比,mgR/mgR小鼠胸主动脉中的MMP-2和MMP-9水平更高。用强力霉素治疗的mgR/mgR小鼠存活132±14.6天(n = 16),明显长于未治疗的突变小鼠(79±6.7天,n = 30)(P < 0.01)。结缔组织染色显示,强力霉素治疗可减少mgR/mgR小鼠的弹性纤维降解。此外,与未治疗的mgR/mgR小鼠相比,用强力霉素治疗的mgR/mgR小鼠的MMP-2和MMP-9水平更低。

结论

本研究表明,强力霉素通过抑制组织MMP-2和MMP-9的表达以及弹性基质的降解,显著延迟了MFS样小鼠的动脉瘤破裂。结果表明,MMPs促进了MFS中胸主动脉瘤的进展,强力霉素有可能显著改变疾病进程。

相似文献

引用本文的文献

1
Therapeutic Opportunities of Marfan Syndrome: Current Perspectives.马凡综合征的治疗机遇:当前观点
Drug Des Devel Ther. 2025 Aug 26;19:7365-7379. doi: 10.2147/DDDT.S523571. eCollection 2025.
3
Distribution and associations of anterior lens zonules lengths in patients with cataract.白内障患者前晶状体带长度的分布和相关性。
Graefes Arch Clin Exp Ophthalmol. 2024 Aug;262(8):2515-2523. doi: 10.1007/s00417-024-06379-z. Epub 2024 Mar 1.
4
Research Progress on Aortic Root Aneurysms.主动脉根部瘤研究进展。
Med Sci Monit. 2024 Feb 9;30:e943216. doi: 10.12659/MSM.943216.
5
Regnase-1 overexpression as a therapeutic approach of Marfan syndrome.过表达Regnase-1作为马凡综合征的一种治疗方法。
Mol Ther Methods Clin Dev. 2023 Dec 1;32(1):101163. doi: 10.1016/j.omtm.2023.101163. eCollection 2024 Mar 14.
9
An update of medical care in Marfan syndrome.马凡综合征医疗护理的最新进展。
Tzu Chi Med J. 2021 Sep 10;34(1):44-48. doi: 10.4103/tcmj.tcmj_95_20. eCollection 2022 Jan-Mar.

本文引用的文献

1
Marfan syndrome: from molecular pathogenesis to clinical treatment.马凡综合征:从分子发病机制到临床治疗
Curr Opin Genet Dev. 2007 Jun;17(3):252-8. doi: 10.1016/j.gde.2007.04.006. Epub 2007 Apr 27.
7
Marfan's syndrome.马方综合征
Lancet. 2005 Dec 3;366(9501):1965-76. doi: 10.1016/S0140-6736(05)67789-6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验